Suppression of CYP2C9 by MicroRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yu, Dianke ^a,b   Green, Bridgett ^a   Marrone, April ^a   Guo, Yongli ^c   Kadlubar, Susan ^d   Lin, Dongxin ^b   Fuscoe, James ^a   Pogribny, Igor ^a   Ning, Baitang ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b CANCER HOSPITAL   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' UNTRANSLATED REGION; CYTOCHROME P450 2C9; MESSENGER RNA; MICRORNA; MIRN128 MICRORNA, HUMAN; MIRN143 MICRORNA, HUMAN; ZALCITABINE;

3' UNTRANSLATED REGION; CHEMISTRY; DOWN REGULATION; DRUG EFFECTS; GEL MOBILITY SHIFT ASSAY; GENETICS; HEK293 CELL LINE; HEPG2 CELL LINE; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; SEQUENCE ALIGNMENT; UPREGULATION;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CYTOCHROME P-450 CYP2C9; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HEK293 CELLS; HEP G2 CELLS; HUMANS; LIVER; LIVER NEOPLASMS; MICRORNAS; RNA, MESSENGER; SEQUENCE ALIGNMENT; UP-REGULATION; ZALCITABINE;

EID: 84923374447     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08534     Document Type: Article

References (45)

1. El-Serag, H. B. & Rudolph, K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576 (2007).
2. Yu, M. C. & Yuan, J. M. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127, S72-78 (2004).
3. Ning, B. et al. Toxicogenomics and cancer susceptibility: advances with nextgeneration sequencing. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 32, 121-158 (2014).
4. Nebert, D. W. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 60, 265-271 (1997).
5. Bartsch, H. et al. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9, 3-28 (2000).
6. Nebert, D. W., McKinnon, R. A. & Puga, A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15, 273-280 (1996).
7. Silvestri, L. et al. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. Int J Cancer 104, 310-317 (2003).
8. Raunio, H. et al. Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Hepatology 27, 427-432 (1998).
9. Tsunedomi, R. et al. Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma. Int J Oncol 27, 661-667 (2005).
10. Xu, X. R. et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci U S A 98, 15089-15094 (2001).
11. Nebert, D. W. & Dalton, T. P. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6, 947-960 (2006).
12. Goldstein, J. A. & de Morais, S. M. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4, 285-299 (1994).
13. Miners, J. O. & Birkett, D. J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45, 525-538 (1998).
14. Chen, X. et al. Gene expression patterns in human liver cancers. Mol Biol Cell 13, 1929-1939 (2002).
15. Kim, J. W. et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 39, 518-527 (2004).
16. Okabe, H. et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61, 2129-2137 (2001).
17. Smith, M. W. et al. Identification of novel tumor markers in hepatitis C virusassociated hepatocellular carcinoma. Cancer Res 63, 859-864 (2003).
18. Mattick, J. S. & Makunin, I. V. Non-coding RNA. Hum Mol Genet 15 Spec No 1, R17-29 (2006).
19. Yokoi, T. & Nakajima, M. microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol 53, 377-400 (2013).
20. Tsuchiya, Y., Nakajima, M., Takagi, S., Taniya, T. & Yokoi, T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 66, 9090-9098 (2006).
21. Calin, G. A. & Croce, C. M. MicroRNA signatures in human cancers. Nat Rev Cancer 6, 857-866 (2006).
22. Donzelli, S. et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 19, 1038-1048 (2012).
23. Godlewski, J. et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68, 9125-9130 (2008).
24. Khan, A. P. et al. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics 9, 298-312 (2010).
25. Gao, W. et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 64, 399-408 (2010).
26. Xu, B. et al. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 350, 207-213 (2011).
27. Aninat, C. et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34, 75-83 (2006).
28. Palumbo, T. et al. Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway. Oncogene 32, 1651-1659 (2013).
29. Yang, L. et al. Sex differences in the expression of drug-metabolizing and transporter genes in human liver. JDrug Metab Toxicol 3,119; DOI:10.4172/2157-7609.1000119 (2012).
30. Ning, B. et al. Systematic and simultaneous gene profiling of 84 drug-metabolizing genes in primary human hepatocytes. J Biomol Screen 13, 194-201 (2008).
31. Yang, L. et al. Gene expression variability in human hepatic drug metabolizing enzymes and transporters. PLoS One 8, e60368; DOI:10.1371/journal.pone.0060368 (2013).
32. Bauer, E. et al. Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. Chem Res Toxicol 8, 136-142 (1995).
33. Ozawa, S. et al. Analyses of bronchial bulky DNA adduct levels and CYP2C9, GSTP1 and NQO1 genotypes in a Hungarian study population with pulmonary diseases. Carcinogenesis 20, 991-995 (1999).
34. Shou, M., Korzekwa, K. R., Crespi, C. L., Gonzalez, F. J. & Gelboin, H. V. The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol. Mol Carcinog 10, 159-168 (1994).
35. Martinez, C. et al. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis 22, 1323-1326 (2001).
36. Chan, A. T., Tranah, G. J., Giovannucci, E. L., Hunter, D. J. & Fuchs, C. S. A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol Hepatol 2, 704-712 (2004).
37. London, S. J., Sullivan-Klose, T., Daly, A. K. & Idle, J. R. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics 7, 401-404 (1997).
38. Witkos, T. M., Koscianska, E. & Krzyzosiak, W. J. Practical Aspects ofmicroRNA Target Prediction. Curr Mol Med 11, 93-109 (2011).
39. Li, M. et al. miR-128 and its target genes in tumorigenesis andmetastasis. Exp Cell Res 319, 3059-3064 (2013).
40. Rao, Q. et al. Aberrant microRNA expression in human cervical carcinomas. Med Oncol 29, 1242-1248 (2012).
41. Leite, K. R. et al. MicroRNA expression profiles in the progression of prostate cancer-from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol 31, 796-801 (2013).
42. Guo, L. et al. Similarities and differences in the expression of drug metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab Dispos 39, 528-538 (2010).
43. Rehmsmeier, M., Steffen, P., Hochsmann, M. & Giegerich, R. Fast and effective prediction of microRNA/target duplexes. RNA 10, 1507-1517 (2004).
44. Huang, L. et al. Copy number variation at 6q13 functions as a long-range regulator and is associated with pancreatic cancer risk. Carcinogenesis 33, 94-100 (2012).
45. Yu, X. et al. Functional genetic variants in the 3′-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. Toxicol Sci 118, 391-403 (2010).